MARKET

ALT

ALT

Altimmune
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.815
-0.025
-0.52%
Opening 15:47 05/19 EDT
OPEN
4.790
PREV CLOSE
4.840
HIGH
5.00
LOW
4.565
VOLUME
622.17K
TURNOVER
1.70M
52 WEEK HIGH
19.46
52 WEEK LOW
3.830
MARKET CAP
208.10M
P/E (TTM)
-1.9954
1D
5D
1M
3M
1Y
5Y
Piper Sandler Maintains Overweight Rating for Altimmune: Here's What You Need To Know
Piper Sandler has decided to maintain its Overweight rating of Altimmune (NASDAQ:ALT) and lower its price target from $34.00 to $25.00. Shares of Altimmune are trading down 0.57% over the last 24 hours, at $5.26 per share. A move to $25.00 would account fo...
Benzinga · 1d ago
Piper Sandler Adjusts Altimmune's Price Target to $25 From $34, Reiterates Overweight Rating
MT Newswires · 1d ago
PTGX, FTCI and ADGI are among after hour movers
Gainers: DLocal Limited (DLO) +20%. Agilysys (AGYS) +14%. Intercure  (INCR) +8%. Protagonist Therapeutics (PTGX) +5%. Fossil Group (FOSL) +5%. Losers: FTC Solar (FTCI) -8%. Knightscope (KSCP) -6%. Altimmune (ALT) -5%. Adagio Therapeutics
Seekingalpha · 1d ago
Altimmune to Present at Upcoming Investor Conferences
GAITHERSBURG, Md., May 16, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences in May 2022:...
GlobeNewswire · 3d ago
110 Biggest Movers From Friday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 154.9% to close at $0.51. ShiftPixy reported board approval special dividend to shareholders in form of common shares of Industrial Human Capital.
Benzinga · 3d ago
Altimmune (NASDAQ:ALT) surges 19% this week, taking three-year gains to 111%
The last three months have been tough on Altimmune, Inc. ( NASDAQ:ALT ) shareholders, who have seen the share price...
Simply Wall St. · 5d ago
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/12 12:42
Altimmune: Q1 Earnings Insights
  Altimmune (NASDAQ:ALT) reported its Q1 earnings results on Thursday, May 12, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/12 11:29
More
No Data
Learn about the latest financial forecast of ALT. Analyze the recent business situations of Altimmune through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

28.57%Strong Buy
71.43%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ALT stock price target is 24.43 with a high estimate of 34.00 and a low estimate of 12.00.
High34.00
Average24.43
Low12.00
Current 4.845
EPS
Actual
Estimate
-0.65-0.49-0.32-0.16
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 122
Institutional Holdings: 33.37M
% Owned: 77.20%
Shares Outstanding: 43.22M
TypeInstitutionsShares
Increased
38
7.18M
New
19
1.99M
Decreased
30
482.17K
Sold Out
34
8.24M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.50%
Pharmaceuticals & Medical Research
+0.35%
Key Executives
Non-Executive Chairman/Independent Director
Mitchel Sayare
President/Chief Executive Officer/Director
Vipin Garg
Chief Financial Officer
Richard Eisenstadt
Chief Scientific Officer
M. Scot Roberts
Other
M. Scott Harris
Independent Director
David Drutz
Independent Director
John Gill
Independent Director
Philip Hodges
Independent Director
Diane Jorkasky
Independent Director
Wayne Pisano
Independent Director
Klaus Schafer
No Data
No Data
About ALT
Altimmune Inc is a clinical-stage immunotherapeutics company. The Company is focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The Company’s product candidates include ALT-801, HepTcell, ALT-702, NasoVAX and NasoShield. HepTcell is a synthetic peptide immunotherapeutic candidate designed to break immune tolerance in chronic Hepatitis B infection. ALT-702, a TLR7/8 agonist conjugate, is a tumor immunostimulant product candidate that has the potential to safely elicit or improve immune responses in a variety of cancer indications. NasoVAX, its influenza vaccine candidate that stimulate multiple arms of the immune system and offers the potential to stop the infection and the spread of flu, while being easier to administer through an intranasal spray. NasoShield is an intranasal anthrax vaccine candidate that is designed to provide more rapid and stable protection than the only approved anthrax vaccine.

Webull offers kinds of Altimmune Inc stock information, including NASDAQ:ALT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALT stock methods without spending real money on the virtual paper trading platform.